SUSTAIN-6 was the first CVOT with a once-weekly GLP-1 receptor agonist and demonstrated significant cardiovascular benefits with a reduction in MACE and non-fatal stroke, and an unexpected increase in diabetic retinopathy
While known for its weight loss benefits, its approved use in India is solely for diabetes management, with weight loss being a secondary effect
Liraglutide Effect and Action in Diabetes (LEADTM) trial
The Non-Incretin Alternatives Are Still Alternatives The conversation has become so GLP-1-centric that the older approved drugs get overlooked, and for some people they are the better fit
This multi-pathway approach may explain its effectiveness for chronic conditions that fail to respond to treatments targeting only one aspect of the healing process
Regular biotin injections can help strengthen brittle nails, support thicker hair growth, and contribute to a clearer, more radiant complexion